BioAffinity Technologies (NASDAQ:BIAFW) Stock Price Down 7.6%
BioAffinity Technologies (NASDAQ:BIAFW) Stock Price Down 7.6%
bioAffinity Technologies, Inc. (NASDAQ:BIAFW – Get Rating) shares fell 7.6% on Tuesday . The stock traded as low as $0.35 and last traded at $0.49. 9,877 shares changed hands during trading, a decline of 70% from the average session volume of 33,233 shares. The stock had previously closed at $0.53.
生物親和技術公司(納斯達克代碼：BIAFW-GET Rating)股價週二下跌7.6%。該股交易價格低至0.35美元，最後報0.49美元。9,877股股票在交易中易手，較33,233股的平均成交量下降了70%。該股此前收盤價為0.53美元。
bioAffinity Technologies Trading Down 7.6 %
生物親和力技術公司股價下跌7.6%
The firm has a 50-day simple moving average of $0.43.
該公司的50日簡單移動均線為0.43美元。
Institutional Investors Weigh In On bioAffinity Technologies
機構投資者看好生物親和技術
An institutional investor recently bought a new position in bioAffinity Technologies stock. Armistice Capital LLC acquired a new stake in bioAffinity Technologies, Inc. (NASDAQ:BIAFW – Get Rating) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 204,082 shares of the company's stock, valued at approximately $72,000.
一家機構投資者最近買入了BioAffity Technologies股票的新頭寸。根據美國證券交易委員會的最新披露，停戰資本有限責任公司在第三季度收購了生物親和技術公司(BIAFW-GET Rating)的新股份。該公司收購了204,082股該公司的股票，價值約72,000美元。
About bioAffinity Technologies
關於生物親和技術
bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level.
生物親和技術公司是一家生物技術公司，致力於開發非侵入性診斷測試和靶向癌症療法。該公司提供CyPath肺部診斷測試，用於早期發現肺癌。它還研究在細胞水準上治療癌症的靶向療法。
See Also
另請參閱
- Get a free copy of the StockNews.com research report on bioAffinity Technologies (BIAFW)
- Will Nordstrom Stock be the Grinch This Year?
- Harpoon Therapeutics Remains Volatile After Promising News
- We Are the Champions: 3 Dividend Growers Wall Street Loves
- What is Market Structure in Trading?
- Institutional Selling Is No Headwind For Nike
- 免費獲取StockNews.com關於生物親和技術的研究報告(BIAFW)
- 諾德斯特龍股票公司會成為今年的格林奇嗎？
- 魚叉治療公司在有希望的消息傳出後仍不穩定
- 我們是冠軍：華爾街鍾愛的3位股息種植者
- 交易中的市場結構是什麼？
- 機構銷售對耐克來說不是逆風
Receive News & Ratings for bioAffinity Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioAffinity Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
接受《生物親和技術日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊，接收最新新聞和分析師對BioAffity Technologies及相關公司的評級的每日摘要。